Early access
Sign in
Taking people in JapanNo phase

Maribavir tablets for cytomegalovirus infection after organ or stem cell transplant

Watches how maribavir works and its side effects in transplant patients with cytomegalovirus.

Key facts

Who runs it
Takeda
Where
Tokyo, JapanSee the site
Trial code
Registry title
A Survey of Maribavir Tablets in Participants With Cytomegalovirus Infection
Status
Recruiting
People taking part
250 people, planned
Started
28 Aug 2024
Expected to end
30 Jun 2028
Type of study
Observational
Treatments tested
  • Maribavir
Record updated
7 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people in Japan who had an organ or stem cell transplant and have a CMV (cytomegalovirus) infection. The infection must not have gone away with existing anti-CMV medicines.

Sex
All sexes can join.
Disease stage
CMV infection after organ transplant (including blood stem cell transplant) that did not respond to existing anti-CMV treatment.
Earlier treatment
Must have had existing anti-CMV treatment that did not work.

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • All participants with Cytomegalovirus (CMV) infection refractory to existing anti-CMV therapy in organ transplantation (including hematopoietic stem cell transplantation)

Who cannot take part

  • None

Where in Japan

  • TokyoHospital not named in the registryTaking people

About the trial

What the trial wants to find out

This study is a survey in Japan of Maribavir tablets used to treat participants with Cytomegalovirus (CMV) infection refractory to existing anti-CMV therapy in organ transplantation (including hematopoietic stem cell transplantation).

Read full original descriptionShow less

The main aim of the study is to check if treatment with Maribavir can protect Japanese people against CMV infection, and to check side effect from the study treatment. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.

During the study, participants with CMV infection will take Maribavir tablets according to their clinic's standard practice. The study doctors will check for side effects from Maribavir tablets for 27 weeks.

The group in the trial

  • Maribavir

    Maribavir 400 milligrams (mg), tablets, orally twice a day.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Special Drug Use Surveillance of LIVTENCITY Tablets 200mg (All-Case Investigation)
Plain-language title
Maribavir tablets for cytomegalovirus infection after organ or stem cell transplantGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
7 August 2026